Schneyer Rebecca, Lerma Klaira
Division of Family Planning Services and Research, Department of Obstetrics and Gynecology, School of Medicine, Stanford University, Stanford, California, USA.
Curr Opin Obstet Gynecol. 2018 Dec;30(6):414-418. doi: 10.1097/GCO.0000000000000493.
To review recent literature on health outcomes associated with use of hormonal contraception with a focus on breast cancer.
A large cohort study documented an increased risk of breast cancer among hormonal contraceptive users compared to those who had never used hormonal contraception. The overall relative risk of breast cancer among current or recent users was 1.2 [95% confidence interval (CI), 1.14-1.26]. Overall, this translates into one additional case of breast cancer for every 7690 users of hormonal contraception. Recent publications have also documented a decrease in risk for endometrial, ovarian, and colorectal cancers among hormonal contraceptive users. Based on these data, it is estimated that a third of endometrial and ovarian cancers and a fifth of colorectal cancers were prevented with combined oral contraceptive use.
Several factors must be taken into consideration regarding the risk of breast cancer associated with hormonal contraceptive use. Contraceptive benefits related to preventing unintended pregnancy are protective against associated maternal morbidity and mortality. Noncontraceptive benefits of protecting against other types of cancers must also be considered. Overall, breast cancer risk is low among hormonal contraceptive users and women should be counseled accordingly.
综述近期关于激素避孕相关健康结局的文献,重点关注乳腺癌。
一项大型队列研究表明,与从未使用过激素避孕的女性相比,激素避孕使用者患乳腺癌的风险增加。当前或近期使用者患乳腺癌的总体相对风险为1.2[95%置信区间(CI),1.14 - 1.26]。总体而言,每7690名激素避孕使用者中就会多出现一例乳腺癌病例。近期出版物还记录了激素避孕使用者患子宫内膜癌、卵巢癌和结直肠癌的风险降低。根据这些数据,估计联合使用口服避孕药可预防三分之一的子宫内膜癌和卵巢癌以及五分之一的结直肠癌。
在考虑激素避孕相关乳腺癌风险时,必须考虑几个因素。与预防意外怀孕相关的避孕益处可预防相关的孕产妇发病和死亡。还必须考虑预防其他类型癌症带来的非避孕益处。总体而言,激素避孕使用者患乳腺癌的风险较低,应据此为女性提供咨询。